Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity in the persistent presence of circulating antiphospholipid antibodies (aPL). Antibodies against β2-glycoprotein I (anti-β2GPI antibodies) and cardiolipin (aCL), together with the functional assay lupus anticoagulant (LA), are the three laboratory tests considered in the revised criteria for the diagnosis of the syndrome. Persistent medium/high positivity, confirmed 12 weeks apart, of at least one of these tests is necessary to diagnose APS [1].

In a large multicentre European cohort of 1000 APS patients, deep vein thrombosis emerged as the most frequent presenting manifestation, and other common vascular events were stroke and pulmonary embolism [2]. The catastrophic variant of APS (CAPS) is a serious aPL-related manifestation, occurring in less than 1% of cases. Multiple small-vessel thrombotic events manifest concomitantly at different anatomic sites in association with a systemic inflammatory response syndrome, which is secondary to the abundant release of cytokines from necrotic tissues [3].

aPL-related vascular events exert a strong clinical impact in terms of morbidity and mortality: it has been estimated that APS affects at least 1% of the general population [2]. In addition, this chronic and disabling condition usually presents in early adulthood: the median age at disease onset is 31 years [4]. Such epidemiological evidence implies that APS diagnosis carries high social and economic costs, making pivotal to correctly manage these patients. The optimal therapeutic approach to APS should aim at attenuating the procoagulant state balancing the side effects
of anticoagulation: a careful weighting of risks and benefits should be performed, taking into account the hazard of recurrence as well as of bleeding.

The evaluation of the pros/cons ratio for each treatment option acquires particular importance when evaluating the primary thromboprophylaxis of aPL carriers. In this context, the aPL profile should be carefully considered, taking into account that low-titre and transient aPL positivity does not display a clinical significance, being described even in healthy individuals and in several pathological conditions, such as infections.

On the other hand, anticoagulation is burdened by significant side effects: such poor safety profile of drugs acting on the coagulation cascade explains why novel therapeutic approaches are currently under investigation, in order to identify pharmacological tools specifically counteracting aPL-mediated prothrombotic effects.

2. aPL Pathogenic Mechanisms

aPL do not provide merely serum APS biomarkers but rather exert a direct pathogenic role in both vascular and obstetric events. aPL are a heterogeneous family of autoantibodies reacting against proteins with affinity for negatively charged phospholipids (PL). In particular, β2-glycoprotein I (β2GPI) provides, together with prothrombin, the main epitope targeted by aPL. Three configurations of β2GPI have been described: circulating plasma β2GPI exists in a circular form; upon binding to suitable anionic surfaces as cardiolipin (CL) and other PL or to LPS, the molecule opens into a J-shaped fish-hook configuration. β2GPI consists of 5 domains (D): DI–IV comprise 60 amino acids and contain two disulfide bridges each, while DV is aberrant, as it includes 82 amino acids due to a 6-residue insertion and a 19-residue C-terminal extension cross-linked by an additional disulfide bond. DI has been identified as the most relevant antigenic target involved in β2GPI/anti-β2GPI antibody binding. This epitope is a cryptic and conformation-dependent structure: in the circular conformation of β2GPI, DI interacts with DV and the critical epitope is thus hidden. Several factors might lead to the surface exposition of the critical epitope, such as oxidative stress. Indeed, under oxidative conditions, disulfide bonds form in the molecule leading to the unmasking of the critical B-cell structure [5].

aPL are well accepted to exert a thrombogenic effects in vitro; aPL mediate such a thrombophilic state by interfering with both soluble components and cells involved in the coagulation cascade [6]. aPL promote aggregation and activation of platelets, neutralizing β2GPI interaction with von Willebrand factor and enhancing the expression of platelet membrane glycoprotein (GP) IIb/IIIa. Moreover, aPL induce a proinflammatory and procoagulant endothelial phenotype upregulating cellular adhesion molecules, promoting the synthesis of endothelial nitric oxide synthase (eNOS) and of proinflammatory cytokines as interleukin (IL)-6 and tumour necrosis factor- (TNF-) α. aPL-induced effects on the endothelium are mainly mediated by the reactivity of the autoantibodies with β2GPI expressed on the endothelial cell (EC) membrane. Many molecules have been advocated as potential mediators of β2GPI interaction with ECs: Annexin A2, Toll-like receptor (TLR) 2 and 4, Heparan-sulfate, and ApoER2'. Lastly, aPL have been shown to significantly increase in both ECs and monocytes the expression of tissue factor (TF), the major initiator of the clotting cascade. There is general agreement that nuclear factor κB (NFκB) and p38 mitogen-activated protein kinase (p38MAPK) are involved in the downstream signalling pathways engaged by aPL in EC and monocyte activation. In addition, aPL have been recently demonstrated to recruit the mammalian target of rapamycin (mTOR) via the phosphatidylinositol 3-kinase- (PI3K-) AKT pathway [7]. However, aPL are not sufficient per se to trigger thrombosis in vivo: clotting takes place exclusively in the presence of a second hit ("two-hit hypothesis") [6].

3. The Impact of aPL-Related Vascular Events in the Real Life

3.1. Frequency of Thrombotic APS. In a recent work by the APS ACTION, the systematic analysis of 73 relevant papers allowed estimating the aPL positivity rate in the general population with related vascular outcomes as follows: 10% in patients with deep vein thrombosis, 11% in subjects myocardial infarction, and 14% in individuals with stroke [8].

3.2. The Strength of Association of aPL with Vascular Events. According to a recent literature revision, the association with aPL appears to be rather solid for vascular events: 54% of studies confirmed the association of aPL with deep venous thrombosis, 55% the association with myocardial infarction, and 71% the association with stroke [9].

4. Risk Stratification

aPL carriers do not display all a similar thrombotic hazard; several parameters should be accounted to accurately stratify the risk of developing a vascular event.

4.1. aPL Profile. Each aPL profile confers a characteristic thrombotic risk. Among the three criteria aPL test, LA has been appointed as the strongest predictor of clinical events, raising the risk of thrombosis by approximately 4-fold [8, 10]. The thrombotic risk increases with the number of positive aPL tests, with triple positive patients displaying the highest vascular hazard. According to the revised classification criteria, APS patients might be stratified into four categories upon the number of positive aPL tests: category I includes patients with more than one positive test in any combination, while patients with a single positive test should be classified in category II [1]. aPL isotypes should also be considered: IgG are clinically more meaningful compared to IgM [II]. Recently, an increasing interest has been catalysed by IgA isotype, whose role in APS warrants further investigation. Among the novel diagnostic and prognostic tool, the subset of anti-β2GPI autoantibodies specifically reacting against DI displays a higher specificity for APS and predicts thrombosis [3].
4.2. Associated Autoimmune Conditions. Patients with an underlying systemic autoimmune condition present an excess vascular morbidity, not fully ascribable to traditional cardiovascular risk factors. In particular, aPL positivity has been identified as one of the main determinants of thrombosis among subjects with systemic lupus erythematosus (SLE) [12].

4.3. Cardiovascular Risk Factors. The two-hit hypothesis fits well with the clinical observation that thrombotic events occur only occasionally despite the persistent presence of aPL. Consistently, most APS patients experiencing a thrombotic event present concomitant cardiovascular risk factors. In particular, hypertension has emerged as an independent predictor for a first thrombotic event in aPL carriers [11]. Infections have also been found to precede APS onset, and their frequency can be as high as 24% in CAPS patients [13]. Consequently, a careful assessment of cardiovascular status should be accomplished in all aPL-positive individuals: age, diabetes, arterial hypertension, dyslipidemia, obesity, smoking, sedentary lifestyle, hyperhomocysteinemia, Protein C, Protein S, and ATIII deficiency, Factor V Leyden and prothrombin mutations, prolonged immobilization, surgical procedures, and oestrogen use.

4.4. Site of Thrombosis. Historically, patients with a first arterial event were regarded at higher risk of experiencing a recurrence, with recurrent event almost invariably involving the same circulatory district [14]. This belief is mainly supported by the only survey analysing arterial and venous events separately, concluding that the risk of recurrence was higher for arterial than venous events [15]. Accordingly, two cohort studies reported a higher incidence of arterial events compared to venous ones: 56 versus 51 recurrences in the EuroAPS cohort (even though venous events were twice more frequent as APS presenting manifestations [2]) and 14 versus 5 in the Singapore cohort [16]. In addition, a case-control study identified previous arterial thrombosis, together with smoking and diabetes, as a predictor of new arterial events [17]. Conversely, in a cohort of high-risk subjects the event at presentation did not predict the site of the recurrence [18].

5. Therapeutic Management of Thrombotic APS Manifestations

Some issues in the pharmacological management of thrombotic APS are still subject of a vigorous debate. These criticisms are difficult to solve because of the several limitations flaving the whole literature, including the two randomized studies assessing the efficacy of anticoagulation [19, 20].

Critical items relate to the following issues:

(a) Study Design. Most studies present (i) a retrospective design and (ii) a small sample size.

(b) aPL Testing. Many studies have included patients not fulfilling APS laboratory criteria in terms of (i) number of aPL tests performed; (ii) aPL positivity confirmation; (iii) aPL cut-off.

(c) Patients’ Selection. Recruited patients were not stratified upon (i) aPL profile; (ii) cardiovascular risk factors; and (iii) site of thrombosis (arterial versus venous).

To overcome these issues and highlight evidence, two systematic reviews included treatment recommendations for aPL-related thrombotic events [21, 22], while an international Task Force elaborated a consensus document on the primary and secondary thromboprophylaxis in individuals carrying aPL [23].

5.1. Pharmacological Agents. The mainstay of the treatment of thrombotic APS is provided by agents that counteract aPL-mediated effects by preventing coagulation.

Antiplatelets as low-dose aspirin (LDASA) are more effective in preventing arterial thrombosis: in the high-flow, high-shear arterial circulation platelet adhesion and aggregation play a major role.

Anticoagulant drugs include vitamin K antagonists (VKA), heparin, and its derivatives.

VKAs act by inhibiting the process of gamma-glutamyl carboxylation of factors II, VII, IX, and X, as well as Protein C and Protein S. The most commonly used VKAs are 4-hydroxycoumarins; among these, warfarin is the most frequently prescribed. VKA treatment presents several pitfalls. These agents have a slow onset of action and a narrow therapeutic window and necessitate frequent INR monitoring. Indeed, they interact with a number of foods and drugs including immunosuppressive agents as azathioprine; VKA activity may fluctuate with alcohol consumption, intercurrent illness, exercise, and smoking. In aPL carriers, VKA monitoring may be rather troublesome because of the variable responsiveness of thromboplastins to LA, even though a multicentre study concluded that LA interference did not significantly affect PT-INR measured with most of commercially available thromboplastins. On the other hand, LA detection in patients on VKA is impaired, thus limiting APS diagnosis among these subjects [24].

Native heparin is a natural anticoagulant whose structure consists of a variable sulfated repeating disaccharide unit, with a molecular weight ranging from 3 to 30 kDa. The inactivation of thrombin by heparin requires at least 18 saccharide units, while the action on factor Xa necessitates only of heparin’s pentasaccharide binding site. Interestingly, heparin’s activity in APS is not merely attributable to its anticoagulant action. Heparin directly interacts with β2GPI: the primary heparin-binding site is located on the second positively charged site within DV of β2GPI protein, the domain also deputized to PL binding. Heparin greatly enhanced the plasmin-mediated cleavage of Lys317-Thr318 site in β2GPI, resulting in a diminished ability of β2GPI to recognize PL and the consequent impairment of the prothrombotic activity of anti-β2GPI antibodies [25].

Heparin derivatives as low molecular weight heparin (LMWH) present a lower molecular weight, with the consequent loss of the action on thrombin and a better therapeutic index. At variance to warfarin, these derivatives have no food/alcohol interactions and few drug interactions and do
5.2. Bleeding Risk. The risk of bleeding has been shown to progressively increase with the rising of anticoagulation intensity, though this is a nonlinear association. Estimates of the bleeding risk in APS patients are derived from studies evaluating treatment efficacy. A 2007 systematic review evaluating eight studies reported an overall major bleeding rate between 0.57 and 10% per year [22]. However, when considering only recent studies where target INR was 2.0-3.0, the annual bleeding rate dropped down to 0.8–1.6% [26]. Interestingly, the single study specifically addressing the risk of bleeding in APS patients reported no fatal bleeding episodes, and precipitating factors were identified in all cases [27]. It is crucial to note that in APS patients the mortality rate due to thrombosis is higher than the mortality rate due to bleeding. A systematic review considering studies published up to 2007 documented 18 deaths due to recurrent thrombosis, compared with only one decease being attributed to haemorrhage [22]. Most recently, 27 of 1000 patients included in the EuroAPS cohort died during the follow-up period as a consequence of thrombosis, with haemorrhage being the cause of death in only 6 patients [17].

To note, INR fluctuations increase with higher intensity of anticoagulation, contributing to the instauration of not only a hemorrhagic status but also a thrombogenic profile. It is thus crucial to estimate the individual risk of bleeding, in order to prevent complications and improve the quality of life of patients. Independent predictors of major bleeding include INR values above 4.0, concomitant treatment with aspirin, age over 75 years, polypharmacy, history of gastrointestinal tract bleeding, malignancy, lack of education regarding anticoagulation therapy, and leukoaraisis. In APS patients, uncontrolled blood pressure has also been associated with an increased risk of bleeding. Consequently, special caution should be paid when considering high-intensity anticoagulation or combined aspirin and warfarin therapy.

5.3. Venous Thrombotic Events. Starting treatment of venous thrombosis in APS patients follows the recommendations for the management of thrombotic events in the general population: initial therapy consists of UFH or LMWH for at least five days, embraced with anticoagulant agents [28]. With regard to long-term management of patients with venous thrombosis, the optimal intensity and duration of anticoagulation are still matter of debate.

5.3.1. Intensity of Anticoagulation. The management of patients with venous thrombosis envisages two options about anticoagulation intensity: moderate (INR 2.0-3.0) versus high (3.0-4.0) intensity.

(i) Moderate-Intensity Anticoagulation. The effectiveness of moderate-intensity anticoagulation is supported by some lines of evidences.

(ii) High-Intensity Anticoagulation. Some retrospective studies suggested that high-intensity regimen was more effective in preventing thrombotic recurrence compared to either LDASA or low-intensity anticoagulation among unselected APS patients [33, 34] and those with a history of venous thrombosis [35].

More recently, a 45% recurrence rate was observed among triple-positive APS patients with a previous venous events receiving standard anticoagulant therapy over a 6-year period reflecting the poor protection offered by standard-intensity
warfarin therapy against recurrent events in this high-risk group [18].

5.3.2. Duration of Anticoagulation. There is currently general consensus to prescribe indefinite anticoagulation to APS patients with a history of venous thrombosis [23]. Nevertheless, an increasing debate has emerged about the potential withdrawal of anticoagulation in a definite subset of aPL patients.

(i) Indefinite Anticoagulation. The choice of indefinite anticoagulation for APS patients is supported by the evidence that these patients carry a higher risk of recurrent thrombosis compared to aPL negative subjects, and such thrombotic risk actually increases with time [14]. The persistency of aCL positivity 6 months after a venous event was found to predict thrombotic recurrence and death, with its predictive value increasing with higher titres [32]. In particular, the risk of recurrence was demonstrated to be highest in the six months following discontinuation of anticoagulant drugs [34]. Consistently, cessation of warfarin was shown to induce a thrombotic phenotype because of the recovery of normal levels of procoagulant factors, in turn leading to a stronger interaction between TF and factor VII [36].

(ii) Three-Month Anticoagulation. In a randomized trial comparing one-month to three-month anticoagulation in patients with venous thrombosis and a transient reversible risk factor, subgroup analysis showed that aPL positivity tested at the time of randomization did not predict venous recurrence [28]. Consistently, over the recent years two-case series demonstrated safe termination of anticoagulation among APS patients who eventually became aPL negative [37, 38]. In this subset of patients, aPL may not play a pathogenic role but rather constitutes an epiphenomenon. It has been therefore proposed that APS patients with a first venous event and a low-risk aPL profile plus a known transient precipitating risk factor could be candidate for 3- to 6-month anticoagulation. In this context, it is advisable to assess ultrasonographically the residual thrombosis and to test D-dimer before suspension of anticoagulation therapy. In the general population, the presence of residual vein thrombosis has been shown to increase the risk of recurrences by 50%, while a negative D-dimer result one month after anticoagulation withdrawal reduces the risk of recurrent thrombosis by twofold. However, the role of ultrasonography and D-dimer test has not yet been assessed in APS population.

5.4. Arterial Thrombotic Events. There is overall consensus that APS patients with a previous arterial event deserve indefinite anticoagulation; the optimal intensity of the anticoagulant regimen is still debated.

5.4.1. Moderate-Intensity Anticoagulation. The randomized trials by Crowther and Finazzi recruited also patients with a history of arterial events, even though the latter were underrepresented compared to subjects experiencing venous thrombosis (24% in the study by Crowther and 32% in the trial promoted by Finazzi). As previously pointed out, these two studies were not in support of a superiority of high intensity as compared to moderate-intensity anticoagulation [19, 20]. Consequently, a 2006 systematic review including only these randomized controlled trials recommended moderate anticoagulation [21].

5.4.2. High-Intensity Anticoagulation. The requirement of high-intensity anticoagulation is suggested by the observation that in many studies oral anticoagulation to a standard target INR range of 2.0 to 3.0 was not sufficient in preventing recurrences among patients presenting with arterial events [4, 14, 33, 34, 39, 40].

Consistently, most new thrombotic events occur with an INR below 3.0, as suggested by several cohort studies [11–13, 33, 39, 40] and one randomized controlled study [19, 27, 41].

The choice of a high-intensity regimen is further supported by the higher recurrence risk experienced by APS patients with a history of arterial events, as suggested in some, but not all, studies [2, 15–18]. Indeed, a 47% recurrence rate was observed in a cohort of triple-positive APS patients with a previous arterial thrombosis receiving standard anticoagulation, suggesting its incomplete efficacy [18].

5.5. Stroke. Thrombotic events in APS commonly involve the cerebral circulation; stroke is the presenting clinical manifestation in 13% of cases while 7% of APS patients develop a transient ischemic attack at disease presentation. In a large European cohort, stroke accounted for 13% of deaths, at a mean age of 42 years [4]. In case of cerebral arterial thrombosis, the therapeutic scenario also comprises antiplatelet agents.

5.5.1. Low-Dose Aspirin. In the randomized controlled Anti-phospholipid Antibodies and Stroke Study (APASS), aspirin at a dose of 325 mg daily was shown to be as effective as low-intensity anticoagulation in the secondary prevention of stroke among aPL-positive patients [42]. However, the APASS study is flawed by some limitations: aPL positivity was not confirmed 12 weeks apart; patients were recruited even when aCL positivity was detected at low-titres. These biases preclude results’ extrapolation to patients with definite APS. Indeed, those subjects with baseline positivity for both LA and aCL tended to have a higher event rate (31.7%) than subjects who tested negative for both antibodies (24%).

5.5.2. Low-Dose Aspirin Plus Moderate-Intensity Anticoagulation. In 2009, Okuma first shed light on the combination of LDASA with moderate-intensity anticoagulation as a therapeutic option in stroke patients with a definite diagnosis of APS. In his randomized controlled trial, a lower incidence of recurrent stroke was observed among patients treated with LDASA plus warfarin compared to those receiving LDASA alone, with a cumulative stroke-free survival of 74% versus 25%. However, this study is flawed by important limitations: firstly, the sample size was rather small, no details about aPL profiles of included patients were provided, and limited data on stroke recurrences in each group were available [43].
Given this conflicting picture, an international Task Force could not reach a consensus about the optimal management of arterial thrombosis. Eight out of the 13 members of the Task Force suggested treatment with warfarin with INR over 3.0 for patients with definite APS; the combination of moderate anticoagulation and aspirin was also listed as an option, while LDASA was reserved to stroke patients with a low-risk profile and reversible thrombotic risk factors [23].

Details of the studies addressing therapeutic regimens in thrombotic APS are enlistered in Table 1.

### 6. Additional Therapeutic Tools

Few pharmacological agents have been investigated as alternatives to warfarin; several others have been proposed as adjunctive tools.

#### 6.1. Hydroxychloroquine

Hydroxychloroquine (HCQ) is an antimalarial drug with anti-inflammatory and antithrombotic properties. In addition, HCQ has been shown to exert immunomodulatory effects: it prevents activation of TLR3, TLR7, and TLR9, inhibits antigen processing and presentation, and reduces circulating immune complexes [55]. In *in vitro* models of thrombotic APS, HCQ has been demonstrated to inhibit GPIIb/IIa expression on aPL-activated platelets [56], to reverse the formation of aPL-β2GPI-PL bilayer complexes [57] and to prevent the aPL-induced disruption of the Annexin A5 shield [58]. Its antithrombogenic properties have been confirmed in *in vivo* models of APS: HCQ injection in mice induced a dose-dependent decrease in thrombus size [59].

In primary thrombotic APS, HCQ has been evaluated as an adjunctive pharmacological tool: patients receiving a combo regimen comprising HCQ plus oral anticoagulation experienced less recurrences compared to those on anticoagulants only. However, the extrapolation of data is affected by the limitations biasing this work: the study cohort was limited to 40 patients, and the follow-up lasted 36 months only [60]. Nevertheless, HCQ is currently catalysing much attention in APS: an ongoing study is assessing the effect of HCQ on Annexin A5 resistance assay in aPL patients with or without SLE; a randomized controlled trial promoted by the international research organization APS ACTION is evaluating HCQ in the primary prevention of thrombosis in aPL asymptomatic carriers at five-year follow-up [61].

Even though there is limited clinical evidence of its antithrombotic effects in primary APS, treatment guidelines consider HCQ as a potential adjunctive therapy, particularly in consideration of its excellent safety profile [23].

#### 6.2. Novel Anticoagulants

Fondaparinux is a synthetic pentasaccharide homologous to heparin binding site; its activity is limited on factor Xa. Fondaparinux has been licensed for thromboprophylaxis, but it has not been yet evaluated in the setting of APS.

Most recently, a novel class of anticoagulants has been synthesized: all are administered orally; these pharmacological agents inhibit a single enzyme of the coagulation cascade, being thus called direct oral anticoagulants (DOA). Dabigatran is a potent, competitive, reversible direct thrombin inhibitor, which binds to thrombin and blocks its interaction with substrates. Direct FXa inhibitors include rivaroxaban, apixaban, and edoxaban. All these agents are highly selective, reversible, competitive, and dose-dependent. They represent an advance over VKA mainly in terms of a better quality of life for patients: since they display a predictable anticoagulant effect, DOA are administered at a fixed dose. In addition, being not metabolized by the cytochrome P450 system, they do not interact with dietary constituents or alcohol and have few reported drug interactions, therefore not requiring routine monitoring of anticoagulant intensity. However, these novel DOA do not allow overcoming some other limitations affecting treatment with VKA. The main issue lies in the significant bleeding risk that any anticoagulant regimen carries, in the absence of an available pharmacological reversal agent [62].

Dabigatran and rivaroxaban have been prescribed to a cohort of 24 French APS patients (11 and 13, resp.); over a median follow-up of 15 months, a single recurrent event was registered [63]. In a UK cohort of 18 APS subjects, rivaroxaban was proved to be safe over 12.9 months [64]. However, caution should be paid when prescribing DOA to APS patients: recently, three cases of thrombotic recurrence upon switching from warfarin to rivaroxaban have been presented [65].

The role of these emerging anticoagulants in APS management is still to be clearly determined: there are few on-going randomized controlled clinical trials evaluating rivaroxaban in the management of APS, as compared to low intensity anticoagulation. The RAPS trial has been promoted by a UK group; it is a phase II/III study that has recruited 156 APS patients with a history of venous thromboembolism. A Spanish phase III trial has been started in Spain on 218 patients with venous or arterial events. Most recently, an Italian trial considering triple positive APS patients only is going to start recruiting [62].

#### 6.3. Statins

Statins inhibit cholesterol synthesis in the mevalonate pathway by blocking the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. The use of statins in the treatment of APS might thus be beneficial in the prevention of thrombosis since hypertriglycerideremia and low HDL cholesterol levels provide the most frequent cardiovascular risk factor reported in APS patients [66]. However, these pharmacological compounds have also been shown to exert a wide array of additional pleiotropic antithrombotic and anti-inflammatory effects in APS. *In vitro*, fluvastatin, simvastatin, and rosuvastatin have been demonstrated to inhibit TF synthesis in EC [67]; fluvastatin and simvastatin were both reported to suppress anti-β2GPI antibody-induced endothelial adhesiveness and to reduce monocyte adhesion to the endothelium [68] while rosuvastatin inhibited the upregulation of VCAM induced by aPL [69]. *In vivo*, fluvastatin reduced the size of the thrombus induced by aPL infusion and the leukocyte adhesion to EC. These findings have been later confirmed in *ex vivo* studies. A trial in 42 patients with
| Author, year [Ref]                     | Type of study | N patients | Sapporo criteria | Thrombotic events A/V | Treatments                      | Observation time | Recurrence rate | Main findings                                                                 |
|--------------------------------------|---------------|------------|------------------|-----------------------|--------------------------------|------------------|-----------------|-----------------------------------------------------------------------------|
| Rosove and Brewer, 1992 [33]         | RC            | 70         | No               | 31/39                 | None                           | 61.2 pt.-years   | 0.19/pt.-year    | Intermediate-high intensity warfarin conferred better antithrombotic protection than low-intermediate warfarin and LDASA |
| Derksen et al., 1993 [35]            | RC            | 19         | Yes              | 0/19                  | None                           | 8–248 months     | NA              | Warfarin INR >3.0 ± LDASA was significantly more effective than warfarin INR <3.0 ± LDASA in preventing thrombotic recurrences |
| Khamashta et al., 1995 [34]          | RC            | 147        | Yes              | 67/80                 | None                           | 280.6 pt.-years  | 0.29/pt.-year    | Warfarin treatment, with or without LDASA, was more effective than placebo and LDASA alone in preventing recurrence          |
| Krnic-Barrie et al., 1997 [15]       | RC            | 61         | No               | 38/23                 | None                           | 124.9 pt.-years  | 91%             | Warfarin was more effective than placebo and LDASA in preventing thrombotic recurrences                                    |
| Munoz-Rodríguez et al., 1999 [40]    | RC            | 47         | Yes              | 19/28                 | None                           | 4–50 months      | 41%             | Despite high-intensity warfarin, the risk of thrombotic recurrences was high                                           |
| Ruiz-Irastorza et al., 2002 [14]     | RC            | 66         | Yes              | 51/32                 | Warfarin INR 3.0–4.0           | 66 pt.-years     | 0.09/pt.-year    | 67% of the recurrences occurred at INR <3.0                                                                                   |
| Wittkowski et al., 2006 [39]         | RC            | 36         | Yes              | 14/16                 | Warfarin INR 2.0–3.0           | 62.5 pt.-years   | 0.096/pt.-year   | Thrombotic recurrence was associated with INR below target                                                                   |
| Girón-González et al., 2004 [41]     | PC            | 158        | Yes              | 70/106                | Warfarin INR 2.5–3.5           | 624 pt.-years    | 0.005/pt.-year   | Recurrence rates were higher in patients receiving high-intensity than low-intensity anticoagulation                       |
| Ames et al., 2005 [27]               | PC            | 67         | Yes              | 17/50                 | Warfarin INR <2.0              | 9 weeks          | 0               | No recurrence was observed with warfarin INR 2.0–3.0                                                                            |
| Ginsberg et al., 1995 [30]           | PC subgroup analysis | 16         | No               | 0/16                  | None                           | 8.7 months       | 18%             | No recurrence was observed with warfarin INR 2.0–3.0                                                                            |
| Author, year [Ref] | Type of study | N patients | Sapporo criteria | Thrombotic events A/V | Treatments | Observation time | Recurrence rate | Main findings |
|-------------------|---------------|------------|------------------|-----------------------|------------|------------------|----------------|---------------|
| Prandoni et al., 1996 [29] | RC subgroup analysis | 15 | Yes | 0/15 | None Warfarin INR 2.0–3.0 | 1–10 years | 0.038/pt.-year | No recurrence was observed with warfarin INR 2.0–3.0 |
| Rance et al., 1997 [31] | RC subgroup analysis | 27 | No | 0/27 | None Warfarin INR 2.0–3.0 | 1–4 years | NA | No recurrence was observed with warfarin INR 2.0–3.0 |
| Schulman et al., 1998 [32] | RCT subgroup analysis | 68 | No | 0/68 | None Warfarin INR 2.0–2.8 | 4 years | 0.01/pt.-year | No recurrence was observed with warfarin INR 2.0–2.8 |
| Levine et al., 2004 [42] | RCT subgroup analysis | 720 | No | 720/0 | ASA Warfarin INR 1.4–2.8 | 2 years | 22.18% 26.15% | ASA and low-intensity anticoagulation were equally effective for secondary stroke prevention |
| Crowther et al., 2003 [19] | RCT | 114 | Yes | 27/87 | Warfarin INR 2.0–3.0 Warfarin INR 3.1–4.0 | 2.7 years | 0.03/pt.-year 0.032/pt.-year | Warfarin at INR 2.0–3.0 was as effective as warfarin at INR 3.1–4.0 in secondary prevention of thrombosis |
| Finazzi et al., 2005 [20] | RCT | 109 | Yes | 44/75 | Warfarin INR 2.0–3.0 Warfarin INR 3.0–4.5 | 3.3 years 3.5 years | 0.016/pt.-year 0.031/pt.-year | Warfarin at INR 2.0–3.0 was as effective as warfarin at INR 3.1–4.5 in secondary prevention of thrombosis |
| Tan et al., 2009 [16] | RC | 59 | Yes | 29/30 | Warfarin INR 2.0–3.0 Warfarin INR 3.1–4.0 | 8.8 years | 23.7% | Warfarin at INR 2.0–3.0 is as effective as warfarin at INR >3 in preventing venous rethromboses and less effective in preventing arterial rethromboses |
| Cervera et al., 2009 [2] | PC | 1000 | Yes | | LDASA Warfarin | 5 years | 14% 21.4% | Antiaggregation and anticoagulation are associated with a significant recurrence rate |
| Author, year [Ref] | Type of study | N patients | Sapporo criteria | Thrombotic events A/V | Treatments | Observation time | Recurrence rate | Main findings |
|-------------------|---------------|------------|-----------------|-----------------------|------------|-----------------|----------------|---------------|
| Pengo et al., 2010 [18] | RC | 160 | Yes | 76/69 | No treatment | Warfarin (median INR 2.3) | 10 years | 44.2% | Oral anticoagulation was the only predictor of thromboembolic events |
| Okuma et al., 2010 [43] | RCT | 20 | No | 0/20 | LDASA | Warfarin INR 2.0–3.0 + LDASA | 3.9 years | NA | Warfarin + LDASA was more effective that LDASA alone in secondary prevention of stroke |
| Fujieda et al., 2012 [44] | RC | 82 | Yes | 82/0 | Warfarin Antiplatelet | Warfarin + antiplatelet Dual antiplatelet | 8.5 years | 3.4/100/pt.-year 0 | Dual antiplatelet regimen was beneficial in preventing recurrences in refractory APS |

A: arterial; V: venous; PC: prospective cohort; RC: retrospective cohort; RCT: randomized controlled trial; LDASA: low-dose aspirin.
APS treated with fluvastatin for 30 days reported a decline in several thrombogenic and inflammatory mediators in monocytes [70]. More recently, Erkan observed a significant reduction of half of the evaluated proinflammatory and procoagulant parameters (IL1β, VEGF, TNFa, IP10, CD40L, and TF) in a cohort of 41 aPL asymptomatic carriers after three months of treatment with fluvastatin [71].

6.4. Vitamin D. In vitro, vitamin D exerts an antithrombotic and immunomodulator function by inhibiting anti-β2GPI antibody-mediated TF expression [72]. Retrospective studies indicated that the prevalence of vitamin D deficiency in APS patients ranges from 10 to 50%, while insufficiency may occur in up to 70% of patients [8, 72–75]. Low vitamin D levels correlate with arterial and venous thrombosis as well as with noncriteria APS manifestations [72, 73, 76]. Conversely, most studies supported no association between low vitamin D levels and obstetric APS [72–74, 76].

6.5. Sirolimus. Sirolimus, an mTOR inhibitor, has been used in patients with APS nephropathy undergoing kidney transplantation. Patients receiving sirolimus in the posttransplant immunosuppressant regimen developed no vascular lesion recurrence. Compared to those in the standard regimen arm, patients on sirolimus had a higher rate of functioning allograft at 144 months (70% versus 11%) and a decreased vascular proliferation on biopsy [7].

7. Refractory Thrombotic APS

A significant rate of APS patients develops recurrent events despite adequate treatment. In past prospective studies, the yearly incidence of recurrent events among APS subjects receiving antithrombotic therapy ranged between 3 and 24% [29, 30, 58], with this rate even increasing up to 52–69% in retrospective studies [31, 32]. Recurrences yield an important mortality; unfortunately, univocal recommendations to manage these situations are still warranted. Firstly, it should be assessed whether the thrombotic event occurred at a subtherapeutic INR range. If the INR is found to be lower than the target, it can be considered to continue with a moderate-intensity regimen, keeping the INR in the therapeutic range.

Additional therapeutic strategies include the following.

7.1. High-Intensity Anticoagulation. If the INR was within the therapeutic range at the time of the recurrence, one option consists in increasing the intensity of anticoagulation. Notably, there is no current evidence in support of this strategy, as both randomized clinical studies by Crowther and Finazzi excluded patients who had a thrombosis while taking warfarin, thus preventing any conclusion about the efficacy of high-intensity anticoagulation in this setting [19, 20].

7.2. Low-Dose Aspirin. In patients with arterial events, a potential option is provided by the addition of LDASA to anticoagulant treatment. However, it should be considered that this combination is burdened by a higher bleeding risk. Moreover, very limited evidence is available: only a small, low-quality randomized controlled trial has shown that combination therapy was more effective than aspirin alone in the secondary prevention of aPL-related stroke [43].

7.3. Dual Antiplatelet Treatment. Dual antiplatelet treatment (different combination of LDASA, ticlopidine, clopidogrel, and cilostazol) has been recently proposed: a Japanese study on 82 APS patients with refractory arterial events documented no recurrences among those subjects receiving dual antiplatelet agents [44].

7.4. Low Molecular Weight Heparin. According to the evidence-based consensus guideline formulated at the 13th International Congress on Antiphospholipid Antibodies, long-term LMWH may also be considered as a safe and effective alternative to warfarin. Details of the reports in support of this therapeutic option in APS are listed in Table 2 [45–48, 77]. Consistently, the 2003 CLOT study stated that dalteparin was even more effective than warfarin in reducing the risk of recurrent embolic events among cancer patients [77].

7.5. Intravenous Immunoglobulins. In vivo and in vitro models suggest the therapeutic potential of intravenous immunoglobulins (IVIg) in APS. IVIg were shown to inhibit aPL, by partially neutralizing LA activity and preventing aCL binding to CL by Fab. IVIg exert an anti-idiotype activity, with inactivation of idiotype-bearing B-cell clones. Furthermore,
IVIg have been demonstrated to increase IgG catabolism, to modulate complement activation, to block Fcy receptor on macrophages, and to downregulate proinflammatory cytokines [78]. Treatment with IVIg resulted in an inhibition of aPL thrombogenic effects, with a reduction of circulating aCL levels [79]. There are few reports about successful treatment with IVIg in the management of aPL-related clinical manifestations, mainly haematological (thrombocytopenia, haemolytic anaemia, and hypoprothrombinemia). Treatment response was observed in all cases with a single exception [80]. Recently, IVIg were found to be effective in preventing thrombosis in 7 patients in addition to conventional therapy [81], as well as in a cohort of 5 patients with refractory APS in a five-year open study [82].

7.6. Anti-B-Cell Agents. The pivotal role exerted by B cells in APS has been progressively deciphered: B lymphocytes contribute to APS etiopathogenesis by producing autoantibodies, inducing the formation of germinal centres and the synthesis of cytokines. Accordingly, in NZW x BXSB mice, treatment with IgG against B-cell activating factor (BAFF) receptor did not prevent the development of aCL even though it prevented aPL-related thrombotic vasculopathy, prolonging survival [83]. In the same murine models, IgG against cytotoxic T-lymphocyte antigen 4 immunoglobulin (CTLA4) affected the B lymphocyte subset and reduced aPL titer [84]. Interestingly, in belimumab-treated patients with SLE a positive-to-negative conversion rate was reported for aCL [85]. To date, clinical experience of B-cell inhibitory agents in APS patients is restricted to the use of rituximab, a chimeric monoclonal antibody targeting CD20 on the surface of B cells. Successful treatment with rituximab has been reported in anecdotal reports and in one case series from the BIOGEAS registry. In this multicentre Spanish registry, a therapeutic response was observed in 92% of 12 cases [86]. In 2012, a review collected all the published cases, identifying 27 APS patients treated with rituximab [87]. The anti-CD20 monoclonal resulted in a decrease of aPL titres; among those receiving rituximab because of thrombocytopenic, clinical improvement was observed in all cases. Moreover, rituximab was beneficial for a plethora of aPL-related clinical manifestations. In this regard, an open-label phase IIa descriptive pilot study (RITAPS) has been carried out in 20 patients with noncriterion APS manifestations refractory to conventional treatments [88]. Rituximab resulted to be effective in controlling some but not all noncriteria manifestations, without substantial change in aPL profile. Notably, caution should be paid to its use in APS: episodes of severe acute thrombotic exacerbations (lacunar infarctions and transverse myelitis) have been reported in two APS/SLE patients receiving rituximab [89].

8. Catastrophic APS

Although CAPS is a rare event, the high mortality rate makes this a clinically relevant issue [4]. Most of the available evidence comes from the CAPS registry, a web-based international registry of CAPS patients created by the European Forum on anti-phospholipid antibodies.

8.1. Combination Therapy. In CAPS registry, the most effective therapeutic approach comprised anticoagulation, corticosteroids, and plasma exchange; this combination was indeed associated with the highest recovery rate (77.8%). Anticoagulation, corticosteroids, plasma exchange, and/or IVIg induced a recovery in 69% of cases. While there was no difference between these two combinations, a trend towards statistical significance was observed between each of these regimens compared to all the remaining options (77.8% versus 55.4%, \( p = 0.083 \) and 69% versus 54.4%, \( p = 0.089 \)). Isolated use of steroids was related to a lower rate of recovery (18.2% versus 58.1% of episodes not treated with corticosteroids; \( p = 0.01 \)) [90]. Plasma exchange is specially indicated when schistocytes are present and should be initiated within 12 hours from the onset [91].

In refractory CAPS, the available evidence comes from anecdotal reports concerning the use of second-line agents as rituximab, eculizumab, and defibrotide.

8.2. Rituximab. Rituximab has been used in 20 cases of CAPS, in different combination with anticoagulation, high doses of steroids, plasma exchange, and IVIg. Despite the difficulties in determining the effects of rituximab, a lower mortality compared to larger series emerged [92].

8.3. Eculizumab. The complement system, in particular the mediator C5a, has been shown to play a central role in APS. C5a, a potent anaphylatoxic, proinflammatory, and chemo tactic molecule, was demonstrated to induce the expression of TF on ECs [93] and neutrophils [94]. In vivo, C5a was involved in deposition of fibrin in a growing thrombus induced by aPL injection [95]. Eculizumab is a humanized monoclonal antibody which binds to the C5 protein with high affinity, thereby inhibiting its cleavage to C5a and C5b thus preventing the generation of membrane attack complex [96]. To date, eculizumab has been administered to few CAPS patients in whom all the other therapeutic strategies proved to be ineffective. A favourable response was described in two cases [97, 98] and a negative outcome in the others [61]. Eculizumab has also been investigated as a tool to manage APS patients after renal transplantation. In a first report on three consecutive kidney transplant recipients with posttransplant aPL-mediated thrombotic microangiopathy (TMA) resistant to plasmapheresis, treatment with eculizumab improved TMA [99]. In another case series of three patients treated with anticoagulation and eculizumab, no systemic thrombotic events or early graft losses were reported after a follow-up ranging from 4 months to 4 years [100].

8.4. Defibrotide. Defibrotide is a polydisperse mixture of 90% single-stranded and 10% double-stranded phosphodiester oligonucleotides derived from the controlled depolymerisation of porcine intestinal mucosal DNA. This pharmacological compound acts by upregulating the release of...
prostacyclin and prostaglandin E2, reducing concentrations of leukotriene B4, inhibiting monocyte superoxide anion generation, stimulating expression of thrombomodulin in human vascular ECs, and modulating platelet activity [101]. More recently, defibrotide was shown to downregulate TF expression on monocytes [102]. To date, it has been used in two patients with CAPS: in one case this treatment was successful, while the second patient died [103, 104].

9. aPL Asymptomatic Carriers

All the studies exploring the thrombotic risk among aPL carriers described a rather low annual rate, around 1% patient-years (range 0–2.8%) [105]. A recent systematic review concluded that this subgroup of patients presents a recurrence rate comparable to aPL negative individuals. This explains why many studies addressing this issue failed to report a clear protective effect for primary prophylaxis and accounts for the evidence that life-long anticoagulation should not be prescribed to those patients not fulfilling laboratory criteria for APS diagnosis.

9.1. Low Molecular Weight Heparin. Evidence-based guidelines recommended LMWH thromboprophylaxis to cover high-risk situations. This was suggested by a 3-year prospective cohort study [11]. A recent meta-analysis concluded that this subgroup of patients presents a recurrence rate comparable to aPL negative individuals. This explains why many studies addressing this issue failed to report a clear protective effect for primary prophylaxis and accounts for the evidence that life-long anticoagulation should not be prescribed to those patients not fulfilling laboratory criteria for APS diagnosis.

9.2. Low-Dose Aspirin. A recent meta-analysis showed a decrease in the risk of thrombotic events by LDASA among asymptomatic aPL carriers, SLE patients, and women with obstetrical APS. Noteworthy, such risk reduction did not maintain statistical significance when prospective studies or those with the best methodological quality were considered [106]. Indeed, the only randomized controlled trial included in this meta-analysis, the APLASA study, reported that LDASA was not more effective than placebo for primary prophylaxis of thrombotic events [53]. Consequently, evidence-based guidelines do not recommend universal thromboprophylaxis with LDASA to asymptomatic aPL individuals [23].

Most recently, a randomized controlled trial examining the efficacy of LDASA versus LDASA plus low-intensity anticoagulation as primary thrombotic prevention (ALIWAPAS) was published. In an overall cohort of 166 asymptomatic carriers, the two arms presented the same rate of thrombosis during the 5 years of follow-up, with more bleeding episodes in the LDASA plus warfarin group. These data make the combo therapy not acceptable as a treatment option for these patients [54].

The scenario changes drastically when considering patients with an underlying autoimmune disease. Indeed, there is a growing bulk of evidence that autoimmune diseases represent a thrombotic risk factor per se: the inflammation peculiar of these pathologic conditions directly contributes to the accelerated atherosclerosis and the significant cardiovascular mortality observed in these patients [107]. Consequently, given the higher thrombotic rate (around 3.7–4%) reported in this population [12, 51, 52, 108, 109], primary prophylactic treatment is recommended among patients with aPL and an associated autoimmune disease [23]. In this setting, LDASA is the drug most commonly prescribed. The efficacy of LDASA in the primary intervention of aPL positive SLE patients has been investigated in three studies, one retrospective and two prospective, all showing a beneficial effect on thrombosis [12, 108, 109]. In 2000, Wahl and colleagues used a Markov decision analysis model to evaluate the prophylactic role of LDASA in aPL-positive SLE patients, suggesting that it was effective in reducing the number of thrombotic events. In particular, LDASA induced a benefit outweighing the treatment-associated risk of major bleeding [110].

9.3. Hydroxychloroquine. An increasing number of experts propose HCQ as primary prophylaxis. Clinical data on the effectiveness of HCQ in preventing aPL-related thrombotic events have been derived from studies in SLE cohorts. Two retrospective studies concordantly showed that the protective effects played by HCQ against thrombosis [11, 12]; a cross-sectional study on 77 APS patients and 56 asymptomatic aPL carriers from a SLE registry proved that the probability of a thrombotic event was decreased by LDASA or HCQ use [50]. In a still unpublished work, Law and coworkers observed a decrease in arterial as well as venous thrombosis in aPL-positive lupus patients receiving HCQ [113]. Accordingly, a systematic review concluded that antimalarials exert an antithrombotic action among SLE patients [114].

Details of the studies investigating management of aPL asymptomatic carriers are listed in Table 3.

10. Potential Future Therapeutic Target

To date, management strategies in APS have been mainly restricted to anticoagulation, which is not effective in all patients. Hopefully, the unravelling of APS pathogenic mechanisms may allow identifying alternative therapeutic targets.

10.1. Novel Molecules Blocking β2/Anti-β2GPI Antibody Binding. (i) TIFI is a 20-amino acid synthetic peptide that spans Thr101–Thr120 of ULB0-HCMVA from human cytomegalovirus, which shares similarities with the PL-binding site in β2GPI molecule, DV. TIFI is not targeted by aPL; in vitro evidence suggests that TIFI inhibits the binding of labelled β2GPI to human ECs and mouse monocytes [115]. These findings were also confirmed in animal models: the infusion of this synthetic peptide inhibited aPL-mediated thrombosis by decreasing the thrombus size produced in response to aPL and by reducing the binding of fluoresceinated β2GPI to ECs [116].

(ii) Accordingly, a synthetic β2GPI-D1 was shown to inhibit aPL-mediated prothrombic effects both in vivo and in vitro [117].
Table 3: Details of clinical studies investigating optimal management of aPL carriers.

| Author, year [Ref] | Type of study       | N patients | Inclusion criteria | Treatment            | Observation time | Event Rate   | Main findings                                                                 |
|--------------------|---------------------|------------|-------------------|----------------------|------------------|--------------|------------------------------------------------------------------------------|
| Erkan et al., 2001 [49] | Retrospective       | 65         | aPL+ women with 1 foetal loss | LDASA                | Mean 8.1 years   | 10%          | LDASA beneficial in aPL+ women with 1 foetal loss                            |
| Erkan et al., 2002 [50] | Cross-sectional     | 56         | aPL+ asymptomatic subjects | LDASA/HCQ            | 6 months        | 0            | LDASA/HCQ beneficial in asymptomatic aPL+ individuals                        |
| Girón-González et al., 2004 [41] | Prospective        | 178        | aPL+ asymptomatic subjects | LMWH/LDASA prophylaxis during high-risk situation | 3 years        | 0            | LMWH/LDASA prophylaxis during high-risk situation beneficial as primary prophylaxis in aPL carriers |
| Mok et al., 2005 [51] | Retrospective       | 272        | SLE patients (aPL+ 29%) | HCQ                  | 27 years        | 1.26/100 patient-years | Patients taking HCQ had fewer thrombotic complications than those who were not (OR 0.17, 95% CI 0.07–0.44; p < 0.0001) |
| Tarr et al., 2007 [52] | Prospective        | 81         | aPL+ SLE patients   | LDASA                | 5 years         | 1.9%         | LDASA/HCQ beneficial in asymptomatic aPL+ SLE patients                      |
| Erkan et al., 2007 [53] | Randomized, controlled | 98         | aPL positive subjects | LDASA                | Mean 2.46 ± 0.76 years | 2.75/100 patient-years | LDASA not beneficial in the primary prophylaxis of aPL positive carriers |
| Tektonidou et al., 2009 [12] | Prospective        | 288        | 144 aPL+ SLE patients 144 aPL− SLE patients | LDASA/HCQ           | 104 months 112 months | 20.1% 7.6% | LDASA and HCQ protective against thrombosis in SLE patients                 |
| Cuadrado et al., 2014 [54] | RCT                | 166        | aPL+ patients      | LDASA LDASA + low intensity warfarin | 5 years        | 4.9%         | LDASA and LDASA + warfarin were equally effective, but lower bleeding risk with LDASA only |
(iii) MBB2 is a novel single chain variable fragment-(scFv-) Fc monoclonal antibody targeting DI of human, rat, and mouse β2GPI. When infused to experimental animals, MBB2 caused blood clots in rat mesenteric microcirculation after LPS priming. A noncomplement-fixing variant of MBB2, MBB2ΔCH2, has also been developed. MBB2ΔCH2 displays the same antigen specificity of MBB2 but, lacking the CH2 domain, is unable to activate the complement cascade. MBB2ΔCH2 has been shown to prevent the aPL-coagulant effects in vivo by competing with circulating aPL for binding to β2GPI. In vivo, the CH2-deleted monoclonal antibody significantly reduced mesenteric thrombus formation and vessel occlusion [118].

(iv) It can also be postulated that antagonists of the receptors involved in β2GPI cell binding may exert a therapeutic potential [119]. The use of antagonists or neutralizing monoclonal antibodies acting on TLR2/4 might be speculated in APS. In addition, DV of β2GPI binds the A1 ligand-binding type A module of ApoER2, a dimer composed of two A1 molecules joined by a flexible linker, has been shown to inhibit anti-β2GPI antibody/dimerized β2GPI immune complexes from binding negatively charged PL and ApoER2 in vitro, more potently than A1 in the monomeric form [120]. More recently, proofs of the effectiveness of this dimeric molecule were obtained in vivo, in two animal models of APS. Indeed, treatment with A1-A1 efficiently reduced thrombus size in vivo in the presence of chronic autoimmune anti-β2GPI antibody in lupus-prone (NZW×BXSB)F1 male mice as well as in wild-type mice after infusion with anti-β2GPI antibodies [121].

(v) Similarly, blockers of the intracellular mediators involved in aPL-activated signalling pathways may reverse the prothrombotic phenotype: NFκB and p38MAPK inhibitors have been shown to be effective in preventing aPL mediated prothrombotic and proinflammatory effects in vitro [122]. More recently, the NFκB inhibitor DEHEQ was demonstrated to ameliorate the prothrombotic state induced by the infusion of the monoclonal antibody WB-6 in normal BALB/c mice [123].

10.2. Novel Molecules Interfering with aPL-Induced Mediators.

(i) It can be speculated that TF inhibition may prevent thrombosis in APS [124]. Currently, there are few drugs available on the market blocking TF expression: ACE inhibitors, dilazep, defibrotide, and dipyridamole. In particular, both dilazep and dipyridamole have been shown to block the upregulation of TF specifically induced by polyclonal IgG purified from APS patients in monocytes [125, 126]. However, their role in APS management has been scarcely documented.

(ii) aPL also upregulate GPIIb/IIIa thus leading to platelet aggregation. Abciximab is a specific GPIIb/IIIa inhibitor routinely prescribed in stroke and acute coronary syndromes, which might be beneficial in APS [127].

(iii) Protein disulphide isomerase is the enzyme responsible for the formation of two disulphide bridges within β2GPI molecule, a reaction leading to an oxidized and immunogenic molecule. This enzyme is inhibited by quercetin-3-rutinoside, whose potential pharmacological effect in APS has to be investigated. In animal models, inhibitors of PDI were effective in treating thrombosis [128].

(iv) Given that oxidation leads to the unmasking of the critical B-cell epitope, it might be worth exploring the role of antioxidant compounds as N-acetylcysteine, vitamin C, and coenzyme Q10 in APS [120]. In an in vitro study, the inhibition of intracellular reactive oxygen species in monocytes prevented the upregulation of TF induced by aPL [129].

(v) Similarly, TNF-α and IL-6 are proinflammatory mediators induced by aPL; it is therefore reasonable to hypothesize that the blockade of these cytokines with biologic agents may be clinically beneficial [122].

The mechanisms of action of the potential future therapeutic tools in APS management are detailed in Figure I.

11. Conclusions

Antiplatelet and anticoagulant agents still provide the cornerstone of APS treatment, even though many clinical issues remain still unresolved. Hopefully, these critical issues will be soon overcome thanks to large, multicentre clinical trials. A well-designed study should account for the relative contribution of the different clinical variables: APS manifestations may be indeed highly diverse, being related to aPL profile as well as to the concomitant cardiovascular risk factors. For the time being, an evidence-based approach would be the following (Figure 2):

(i) patients with venous events should receive long-term anticoagulation at an INR target of 2.0–3.0;
(ii) patients with a history of arterial thrombosis should receive long-term anticoagulation at an INR target of 2.0–3.0;
(iii) subjects who develop a stroke and present a low-risk aPL profile without any associated autoimmune condition may be prescribed with LDASA;
(iv) stroke patients at higher thrombotic risk and individuals with a history of arterial thrombosis should receive long-term anticoagulation;
(v) a primary thromboprophylaxis with LDASA should be instituted in asymptomatic carriers with a clinically significant aPL profile or additional thrombotic risk factors; HCQ should be prescribed to subjects with underlying autoimmune diseases.

In addition, a strict management of prothrombotic risk factors is warranted in all aPL carriers; unfortunately, no study has yet addressed the potential effects of controlling cardiovascular status on outcome. Similarly, the pleiotropic effects of agents such as statins and HCQ should be further assessed: the addition of these drugs to standard anticoagulation may lead to a better disease control. Moreover, the identification of novel diagnostic tools, such as antibodies against DI of β2GPI or against phosphatidylserine/prothrombin, may allow more precise risk stratification, leading to a tailored treatment strategy. Research has been galvanized to identify novel therapeutic targets: hopefully, such pharmacological agents might revolutionize APS management in the near future.
**Figure 1:** Mechanisms of action of potential future therapeutic tools in APS. ROS: reactive oxygen species; β2GPI: β2 glycoprotein I; aβ2GPI: antibodies against β2GPI; PDI: protein disulfide isomerase; ACEi: angiotensin-converting enzyme inhibitors; TLR: Toll-like receptor; TF: tissue factor; eNOS: endothelial nitric oxide synthase; GP: glycoprotein; IL: interleukin; TNF: tumour necrosis factor; PI3K: phosphatidylinositol 3-kinase; mTOR: mammalian target of rapamycin.

| Venous thrombosis | Stroke | Arterial thrombosis | CAPS | No event |
|-------------------|--------|---------------------|------|---------|
| Warfarin [INR: 2.0-3.0] | Warfarin [INR: 2.0-3.0] | Warfarin [INR: 2.0-3.0] + corticosteroids + PE | Warfarin [INR: 2.0-3.0] + corticosteroids + PE | Low-risk aPL profile transient risk-factors |
| LDASA | Clinically significant aPL profile | No autoimmune disease | LDASA | HCQ |

**Figure 2:** Flow-diagram of the therapeutic approach to thrombotic APS. aPL: antiphospholipid antibodies; CAPS: catastrophic antiphospholipid syndrome; LDASA: low-dose aspirin; PE: plasma exchange; HCQ: hydroxychloroquine.
Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” *Journal of Thrombosis and Haemostasis*, vol. 4, no. 2, pp. 295–306, 2006.

[2] R. Cervera, M. A. Khamashta, Y. Shoenfeld et al., “Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients,” *Annals of the Rheumatic Diseases*, vol. 68, no. 9, pp. 1428–1432, 2009.

[3] P. L. Meroni, C. B. Chighizola, F. Rovelli, and M. Gerosa, “Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers,” *Arthritis Research and Therapy*, vol. 16, no. 2, article 209, 2014.

[4] R. Cervera, J.-C. Piette, J. Font et al., “Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients,” *Arthritis and Rheumatism*, vol. 46, no. 4, pp. 1019–1027, 2002.

[5] C. B. Chighizola, M. Gerosa, and P. L. Meroni, “New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies,” *Current Rheumatology Reports*, vol. 16, no. 2, pp. 402–409, 2014.

[6] P. L. Meroni, M. O. Borghi, E. Raschi, and F. Tedesco, “Pathogenesis of antiphospholipid syndrome: understanding the antibodies,” *Nature Reviews Rheumatology*, vol. 7, no. 6, pp. 330–339, 2011.

[7] G. Canaud, F. Bienaimé, F. Tabarin et al., “Inhibition of the mTORC pathway in the Antiphospholipid syndrome,” *The New England Journal of Medicine*, vol. 371, no. 4, pp. 303–312, 2014.

[8] L. Andreoli, C. B. Chighizola, A. Banzato, G. J. Pons-Estel, G. R. de Jesus, and D. Erkan, “Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature,” *Arthritis Care & Research*, vol. 65, no. 11, pp. 1869–1873, 2013.

[9] C. B. Chighizola, L. Andreoli, A. Banzato et al., “The association between antiphospholipid antibodies and related clinical outcomes: a critical review of the literature,” *Arthritis & Rheumatism*, vol. 65, p. S129, 2013.

[10] P. G. De Groot, B. Lutters, R. H. W. M. Derksen, T. Lisman, J. C. M. Meijers, and F. R. Rosendaal, “Lupus anticoagulants and the risk of a first episode of deep venous thrombosis,” *Journal of Thrombosis and Haemostasis*, vol. 3, no. 9, pp. 1993–1997, 2005.

[11] A. Ruffatti, T. Del Ross, M. Ciprian et al., “Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study,” *Annals of the Rheumatic Diseases*, vol. 68, no. 3, pp. 397–399, 2009.

[12] M. G. Tektonidou, K. Laskari, D. B. Panagiotakos, and H. M. Moutsopoulos, “Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies,” *Arthritis Care and Research*, vol. 61, no. 1, pp. 29–36, 2009.

[13] Y. Shoenfeld, M. Blank, R. Cervera, J. Font, E. Raschi, and P.-L. Meroni, “Infectious origin of the antiphospholipid syndrome,” *Annals of the Rheumatic Diseases*, vol. 65, no. 1, pp. 2–6, 2006.

[14] G. Ruiz-Irastorza, M. A. Khamashta, B. J. Hunt, A. Escudero, M. J. Cuadrado, and G. R. V. Hughes, “Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5,” *Archives of Internal Medicine*, vol. 162, no. 10, pp. 1164–1169, 2002.

[15] S. Knic-Barrie, C. R. O’Connor, S. W. Looney, S. S. Pierangdi, and E. N. Harris, ”A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis," *Archives of Internal Medicine*, vol. 157, no. 18, pp. 2011–2018, 1997.

[16] B. E. Tan, B. Y. H. Thong, S. Shivananda, W. W. Han, and H. H. Chng, “Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort,” *Lupus*, vol. 18, no. 8, pp. 752–758, 2009.

[17] C. Neville, J. Rauch, J. Kassis et al., “Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort,” *Thrombosis and Haemostasis*, vol. 101, no. 1, pp. 100–107, 2009.

[18] V. Pengo, A. Ruffatti, C. Legnani et al., “Clinical course of high-risk patients diagnosed with antiphospholipid syndrome,” *Journal of Thrombosis and Haemostasis*, vol. 8, no. 2, pp. 237–242, 2010.

[19] M. A. Crowther, J. S. Ginsberg, J. Julian et al., “A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome,” *The New England Journal of Medicine*, vol. 349, no. 12, pp. 1133–1138, 2003.

[20] G. Finazzi, R. Marchioli, V. Brancaccio et al., “A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS),” *Journal of Thrombosis and Haemostasis*, vol. 3, no. 5, pp. 848–853, 2005.

[21] W. Lim, M. A. Crowther, and J. W. Eikelboom, “Management of antiphospholipid antibody syndrome: a systematic review,” *Journal of the American Medical Association*, vol. 295, no. 9, pp. 1050–1057, 2006.

[22] G. Ruiz-Irastorza, B. J. Hunt, and M. A. Khamashta, “A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies,” *Arthritis Care and Research*, vol. 57, no. 8, pp. 1487–1495, 2007.

[23] G. Ruiz-Irastorza, M. J. Cuadrado, I. Ruiz-Arruza et al., “Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on Antiphospholipid Antibodies,” *Lupus*, vol. 20, no. 2, pp. 206–218, 2011.

[24] H. Cohen and S. I. MacHin, “Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?” *Lupus*, vol. 19, no. 4, pp. 486–491, 2010.

[25] J. Guerin, Y. Sheng, S. Reddel, G. M. Iversen, M. G. Chapman, and S. A. Krilis, “Heparin inhibits the binding of β2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome,” *The Journal of Biological Chemistry*, vol. 277, no. 4, pp. 2644–2649, 2002.

[26] M. Bazzan, A. Vaccarino, S. Stella et al., “Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort,” *Autoimmunity Reviews*, vol. 12, no. 8, pp. 826–831, 2013.
open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)," *Rheumatology*, vol. 53, no. 2, pp. 275–284, 2014.

[55] A. Kužník, M. Benčina, U. Švaiger, M. Jeras, B. Rozman, and R. Jerala, "Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazooquinolines," *Journal of Immunology*, vol. 186, no. 8, pp. 4794–4804, 2011.

[56] R. G. Espinola, S. S. Pierangeli, A. E. Ghara, and E. N. Harris, "Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies," *Thrombosis and Haemostasis*, vol. 87, no. 3, pp. 518–522, 2002.

[57] J. H. Rand, X.-X. Wu, A. S. Quinn, P. P. Chen, J. J. Hathcock, and D. J. Taatjes, "Hydroxychloroquine directly reduces the bindin of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers," *Blood*, vol. 112, no. 5, pp. 1687–1695, 2008.

[58] J. H. Rand, X.-X. Wu, A. S. Quinn et al., "Hydroxychloroquine protects the annexinA5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug," *Blood*, vol. 115, no. 11, pp. 2292–2299, 2010.

[59] M. H. Edwards, S. Pierangeli, X. Liu, J. H. Barker, G. Anderson, and E. Nigel Harris, "Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice," *Circulation*, vol. 96, no. 12, pp. 4380–4384, 1997.

[60] A. Schmidt-Tanguy, J. Voswinkel, D. Henrion et al., "Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients," *Journal of Thrombosis and Haemostasis*, vol. 11, no. 10, pp. 1927–1929, 2013.

[61] D. Erkan, C. L. Aguiar, D. Andrade et al., "14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends," *Autoimmunity Reviews*, vol. 13, no. 6, pp. 685–696, 2014.

[62] C. B. Chighizola, M. Moia, and P. L. Meroni, "New oral anticoagulants in thrombotic antiphospholipid syndrome," *Lupus*, vol. 23, no. 12, pp. 1279–1282, 2014.

[63] N. Noel, F. Dutasta, N. Costedoat-Chalumeau et al., "Safety and efficacy of new oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome," *Arthritis & Rheumatism*, vol. 66, no. II, article 54, 2014.

[64] S. Sciascia and B. Hunt, "Rivaroxaban use in patients with antiphospholipid syndrome patients and previous poor anticoagulation control with vitamin K antagonists," *Arthritis & Rheumatology*, vol. 66, no. II, p. 57, 2014.

[65] J. K. Schaefer, R. D. McBane, D. F. Black, L. N. Williams, K. G. Moder, and W. E. Wysokinski, "Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients," *Thrombosis and Haemostasis*, vol. 112, no. 5, pp. 947–950, 2014.

[66] G. Medina, A. L. Gutiérrez-Moreno, O. Vera-Lastra, M. A. Saavedra, and L. J. Jara, "Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients," *Autoimmunity Reviews*, vol. 10, no. 4, pp. 214–217, 2011.

[67] D. E. Ferrara, R. Swerlick, K. Casper et al., "Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells," *Journal of Thrombosis and Haemostasis*, vol. 2, no. 9, pp. 1558–1563, 2004.

[68] P. L. Meroni, E. Raschi, C. Testoni et al., "Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype," *Arthritis & Rheumatism*, vol. 44, no. 12, pp. 2870–2878, 2001.

[69] L. A. Martínez-Martínez, M. C. Amigo, A. Orozco et al., "Effect of rosuvastatin on vascular cell adhesion molecule 1 (vcam-1) expression by human endothelial cells exposed to antiphospholipid syndrome serum," *Journal of Clinical Rheumatology*, vol. 12, article S80, 2006.

[70] C. López-Pedrera, P. Ruiz-Limón, M. Á. Aguirre et al., "Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome," *Annals of the Rheumatic Diseases*, vol. 70, no. 4, pp. 675–682, 2011.

[71] D. Erkan, R. Willis, V. L. Murthy et al., "A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients," *Annals of the Rheumatic Diseases*, vol. 73, no. 6, pp. 1176–1180, 2014.

[72] N. Agmon-Levin, M. Blank, G. Zandman-Goddard et al., "Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression," *Annals of the Rheumatic Diseases*, vol. 70, no. 1, pp. 145–150, 2011.

[73] S. Piantoni, L. Andreoli, F. Allegri, P. L. Meroni, and A. Tincani, "Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease," *Reumatismo*, vol. 64, no. 5, pp. 307–313, 2012.

[74] K. Klack and J. F. D. Carvalho, "High frequency of vitamin D insufficiency in primary antiphospholipid syndrome," *Joint Bone Spine*, vol. 77, no. 5, pp. 489–490, 2010.

[75] J. A. Paupitz, J. F. de Carvalho, V. F. Caparbo, K. Klack, and R. M. R. Pereira, "Primary antiphospholipid syndrome in premenopausal women: low vitamin D, high fat mass and maintained bone mineral mass," *Lupus*, vol. 19, no. II, pp. 1302–1306, 2010.

[76] L. Andreoli, S. Piantoni, F. Dall'Ara, F. Allegri, P. L. Meroni, and A. Tincani, "Vitamin D and antiphospholipid syndrome," *Lupus*, vol. 21, no. 7, pp. 736–740, 2012.

[77] A. Y. Y. Lee, M. N. Levine, R. I. Baker et al., "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer," *The New England Journal of Medicine*, vol. 349, no. 2, pp. 146–153, 2003.

[78] E. Konova, "Intravenous immunoglobulin therapy in antiphospholipid syndrome," *Clinical Reviews in Allergy and Immunology*, vol. 29, no. 3, pp. 229–236, 2005.

[79] S. S. Pierangeli, R. Espinola, X. Liu, E. Nigel Harris, and J. E. Salmon, "Identification of an Fcγ receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype," *Arthritis and Rheumatism*, vol. 44, no. 4, pp. 876–883, 2001.

[80] Y. Shefer, Y. Levy, and Y. Shoenfeld, "Intravenous immunoglobulin therapy of antiphospholipid syndrome," *Rheumatology*, vol. 39, no. 4, pp. 421–426, 2000.

[81] S. Tenti, G. M. Guidelli, F. Bellisai, M. Galeazzi, and A. Fioravanti, "Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy," *Clinical & Experimental Rheumatology*, vol. 31, no. 6, pp. 877–882, 2013.

[82] S. Sciascia, O. Giachino, and D. Roccatello, "Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin," *Clinical and Experimental Rheumatology*, vol. 30, no. 3, pp. 409–413, 2012.

[83] S. Sciascia, B. Hunt, and K. L. Blumberg, "Arthritis & Rheumatism*, vol. 58, no. 9, pp. 2824–2834, 2008."
[84] A. Akkerman, W. Huang, X. Wang et al., “CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice,” *Autoimmunity*, vol. 37, no. 6-7, pp. 445–451, 2004.

[85] W. Stohl, F. Hiepe, K. M. Latinis et al., “Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 64, no. 7, pp. 2328–2337, 2012.

[86] M. Ramos-Casals, P. Brito-Zerón, S. Muñoz, and M.-J. Soto, “A systematic review of the off-label use of biological therapies in systemic autoimmune diseases,” *Medicine*, vol. 87, no. 6, pp. 345–364, 2008.

[87] S. Khattri, G. Zandman-Goddard, and E. Peeva, “B-cell directed therapies in antiphospholipid antibody syndrome—new directions based on murine and human data,” *Autoimmunity Reviews*, vol. 11, no. 10, pp. 717–722, 2012.

[88] D. Erkan, J. Vega, G. Ramón, E. Kozora, and M. D. Lockshin, “A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome,” *Arthritis & Rheumatism*, vol. 65, no. 2, pp. 464–471, 2013.

[89] K. Suzuki, H. Nagasawa, H. Kameda et al., “Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus,” *Rheumatology*, vol. 48, no. 2, pp. 198–199, 2009.

[90] S. Bucciarelli, G. Espinosa, R. Cervera et al., “Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients,” *Arthritis and Rheumatism*, vol. 54, no. 8, pp. 2568–2576, 2006.

[91] G. J. Pons-Estel, G. E. Salerni, R. M. Serrano et al., “Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature,” *Autoimmunity Reviews*, vol. 10, no. II, pp. 679–684, 2011.

[92] H. Berman, I. Rodríguez-Pintó, R. Cervera et al., “Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab,” *Autoimmunity Reviews*, vol. 12, no. II, pp. 1085–1090, 2013.

[93] K. Ikeda, K. Nagasawa, T. Horiuichi, T. Tsuru, H. Nishizaka, and Y. Niho, “C5a induces tissue factor activity on endothelial cells,” *Thrombosis and Haemostasis*, vol. 77, no. 2, pp. 394–398, 1997.

[94] K. Ritis, M. Doumas, D. Mastellos et al., “A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways,” *Journal of Immunology*, vol. 177, no. 7, pp. 4794–4802, 2006.

[95] F. Fischetti, P. Durigutto, V. Pellis et al., “Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor,” *Blood*, vol. 106, no. 7, pp. 2340–2346, 2005.

[96] J. Schmidtke, S. Peine, Y. El-Housseini, M. Pascual, and P. Meier, “Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab,” *American Journal of Kidney Diseases*, vol. 61, no. 2, pp. 289–299, 2013.

[97] B. E. Lonze, A. L. Singer, and R. A. Montgomery, “Eculizumab and renal transplantation in a patient with CAPS,” *The New England Journal of Medicine*, vol. 362, no. 18, pp. 1744–1745, 2010.

[98] I. Shapira, D. Andrade, S. L. Allen, and J. E. Salmon, “Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab,” *Arthritis & Rheumatism*, vol. 64, no. 8, pp. 2719–2723, 2012.

[99] G. Canaud, N. Kamar, D. Anglicheau et al., “Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes,” *American Journal of Transplantation*, vol. 13, no. 8, pp. 2179–2185, 2013.

[100] B. E. Lonze, A. A. Zachary, C. M. Magro et al., “Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation,” *American Journal of Transplantation*, vol. 14, no. 2, pp. 459–465, 2014.

[101] F. Morabito, M. Gentile, F. Gay et al., “Insights into defibrotide: an updated review,” *Expert Opinion on Biological Therapy*, vol. 9, no. 6, pp. 763–772, 2009.

[102] A. Falanga, A. Vignoli, M. Marchetti, and T. Barbui, “Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells,” *Leukemia*, vol. 17, no. 8, pp. 1636–1642, 2003.

[103] R. A. Asherson, R. Cervera, J.-C. Piette et al., “Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients,” *Medicine*, vol. 80, no. 6, pp. 355–377, 2001.

[104] A. Burcoglu-O’Ral, D. Erkan, and R. Asherson, “Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator,” *The Journal of Rheumatology*, vol. 29, no. 9, pp. 2006–2011, 2002.

[105] M. Gerosa, C. Chighizola, and P. L. Meroni, “Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases),” *Internal and Emergency Medicine*, vol. 3, no. 3, pp. 201–203, 2008.

[106] L. Arnaud, A. Mathian, A. Ruffatti et al., “Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis,” *Autoimmunity Reviews*, vol. 13, no. 3, pp. 281–291, 2014.

[107] C. Chighizola, T. Schioppo, F. Ingegnoli, and P. L. Meroni, “Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis,” *Current Vascular Pharmacology*, vol. 10, no. 5, pp. 639–646, 2012.

[108] F. Martínez, M. J. Forner, M. Ruano, N. Abdilla, R. Oltra, and M. J. García-Fuster, “Factors related to the risk of thrombosis in patients with lupus and antiphospholipid antibodies,” *Medicina Clinica*, vol. 127, no. 11, pp. 405–408, 2006.

[109] N. M. Shah, M. A. Khamashta, T. Atsumi, and G. R. V. Hughes, “Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients,” *Lupus*, vol. 7, no. 1, pp. 3–6, 1998.

[110] D. G. Wahl, H. Bounaumeaux, P. de Moerloose, and F. P. Sarasin, “Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis,” *Archives of Internal Medicine*, vol. 160, no. 13, pp. 2042–2048, 2000.

[111] D. J. Wallace, “Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?” *Arthritis and Rheumatism*, vol. 30, no. 12, pp. 1435–1436, 1987.

[112] G. Ruiz-Irastorza, M.-V. Egurbide, J.-I. Pijoan et al., “Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus,” *Lupus*, vol. 15, no. 9, pp. 577–583, 2006.

[113] G. Law, L. Magder, H. Fang, and M. Petri, “Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, particularly in antiphospholipid positive
patients,” *Annals of the Rheumatic Diseases*, vol. 71, supplement 3, p. S47, 2014.

[114] G. Ruiz-Irastorza, M. Ramos-Casals, P. Brito-Zeron, and M. A. Khamashta, “Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review,” *Annals of the Rheumatic Diseases*, vol. 69, no. 1, pp. 20–28, 2010.

[115] M. V. Ostertag, X. Liu, V. Henderson, and S. S. Pierangeli, “A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice,” *Lupus*, vol. 15, no. 6, pp. 358–365, 2006.

[116] Y. M. de la Torre, F. Pregnolato, F. D’Amelio et al., “Antiphospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss,” *Journal of Autoimmunity*, vol. 38, no. 2-3, pp. J209–J215, 2012.

[117] Y. Ioannou, Z. Romay-Penabad, C. Pericleous et al., “In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β2-glycoprotein I: proof of concept,” *Journal of Thrombosis and Haemostasis*, vol. 7, no. 5, pp. 833–842, 2009.

[118] C. Agostinis, P. Durigutto, D. Sblattero et al., "A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome," *Blood*, vol. 123, no. 22, pp. 3478–3487, 2014.

[119] B. Giannakopoulos and S. A. Krilis, “The pathogenesis of the antiphospholipid syndrome,” *The New England Journal of Medicine*, vol. 368, no. 11, pp. 1033–1044, 2013.

[120] A. Kolyada, C.-J. Lee, A. de Biasio, and N. Beglova, “A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome,” *PLoS ONE*, vol. 5, no. 12, Article ID e15345, 2010.

[121] A. Kolyada, A. Porter, and N. Beglova, “Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome,” *Blood*, vol. 123, no. 7, pp. 1090–1097, 2014.

[122] C. Comarmond and P. Cacoub, “Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies,” *Autoimmunity Reviews*, vol. 12, no. 7, pp. 752–757, 2013.

[123] M. Nishimura, T. Nii, G. Trimova et al., “The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome,” *Journal of Nephropathology*, vol. 2, no. 2, pp. 114–121, 2013.

[124] S. S. Pierangeli and D. Erkan, “Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?” *Lupus*, vol. 19, no. 4, pp. 475–485, 2010.

[125] H. Zhou, A. S. Wolberg, and R. A. S. Roubey, “Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep,” *Blood*, vol. 104, no. 8, pp. 2353–2358, 2004.

[126] H. Zhou, “Dilazep and dipyridamole inhibit tissue factor expression on monocytes induced by IgG from patients with antiphospholipid syndrome,” *Acta Pharmacologica Sinica*, vol. 25, no. 10, pp. 1366–1371, 2004.

[127] T. Scoble, S. Wijetilleka, and M. A. Khamashta, “Management of refractory anti-phospholipid syndrome,” *Autoimmunity Reviews*, vol. 10, no. 11, pp. 669–673, 2011.

[128] R. Jasuja, F. H. Passam, D. R. Kennedy et al., “Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents,” *Journal of Clinical Investigation*, vol. 122, no. 6, pp. 2104–2113, 2012.

[129] C. Perez-Sanchez, P. Ruiz-Limon, M. A. Aguirre et al., “Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment,” *Blood*, vol. 119, no. 24, pp. 5859–5870, 2012.